The primary reason to take progesterone after menopause is to protect your uterus from the effects of estrogen therapy. When estrogen is taken alone, it stimulates the uterine lining to grow, which significantly raises the risk of endometrial hyperplasia (abnormal thickening) and potentially cancer. Adding progesterone counteracts that growth, keeping the lining thin and safe. But uterine protection isn’t the only reason progesterone is prescribed. It also offers benefits for sleep, bone density, and possibly mood.
Protecting the Uterine Lining
This is the non-negotiable reason. During your reproductive years, progesterone rises naturally after ovulation each month, triggering the uterine lining to stop thickening and eventually shed. After menopause, your body produces very little progesterone. If you take estrogen replacement without progesterone, the lining keeps building up with no signal to stop.
The numbers make this risk concrete. In women taking estrogen alone, roughly 22 to 68 out of every 1,000 develop endometrial hyperplasia within the first year or beyond, compared to just 5 out of 1,000 on placebo. When you compare estrogen alone to estrogen paired with continuous progesterone, the gap is even starker: 46 to 75 per 1,000 versus only 3 per 1,000 develop hyperplasia. That’s a risk roughly 20 times higher without progesterone. Over longer periods, the pattern holds or worsens.
If you’ve had a hysterectomy, this particular concern doesn’t apply. Without a uterus, there’s no endometrial lining to protect, so progesterone isn’t routinely prescribed for that purpose. Some clinicians still consider it for other potential benefits, but the standard recommendation is that progesterone is essential specifically for women who still have a uterus.
Better Sleep Quality
One of the benefits women notice most quickly is improved sleep. In a Phase III placebo-controlled trial across Canada, women taking oral micronized progesterone reported significantly better sleep quality compared to placebo. They also perceived fewer night sweats and less interference from menopause symptoms in daily life. The sleep benefit likely comes from one of progesterone’s breakdown products, which acts on the same brain receptors targeted by anti-anxiety and sedative medications. This is why oral progesterone is typically taken at bedtime: the mild drowsiness it can cause is a feature, not a bug.
Mood and Anxiety Effects
When your body processes progesterone, it converts some of it into a compound that enhances the activity of your brain’s primary calming system. At certain concentrations, this metabolite produces anxiety-reducing and sedative effects. It may also promote the release of chemicals associated with feelings of pleasure and reward.
The relationship between progesterone and mood is not perfectly straightforward, though. Research suggests an inverted U-shaped pattern: very low and very high levels tend to be calming, while moderate levels (similar to those in a natural menstrual cycle) can actually increase anxiety in some women, much like the paradoxical reactions some people have to sedative medications. In the Canadian trial mentioned above, progesterone did not increase depression, and anxiety levels were similar between progesterone and placebo groups on daily tracking. So while progesterone is not primarily prescribed as a mood treatment, many women experience a calming effect, particularly at bedtime.
Bone Density Gains
Estrogen is well established as a treatment to prevent bone loss after menopause, primarily by slowing the breakdown of existing bone. Progesterone appears to work through a different mechanism: it may stimulate the cells that build new bone. When the two are combined, the effects appear to be additive.
A meta-analysis of randomized controlled trials involving more than 1,000 menopausal women found that those taking estrogen plus a progestin gained about two-thirds of a percentage point more spinal bone density per year than those taking estrogen alone. That’s a meaningful difference over several years of treatment, and it represents some of the strongest evidence that progesterone contributes something beyond uterine protection in hormone therapy.
Breast Cancer Risk Considerations
One of the most important distinctions in progesterone therapy is the type used. Micronized progesterone (the form that’s identical to what your body once produced) appears to carry a meaningfully lower breast cancer risk than synthetic progestins. A systematic review and meta-analysis found that women using estrogen combined with micronized progesterone had a 33% lower relative risk of breast cancer compared to women using estrogen with synthetic progestins. One study included in that analysis found no significant increase in breast cancer risk at all among women using estrogen with progesterone, while synthetic progestin users trended toward higher risk.
This distinction matters when you’re discussing options with your healthcare provider. Not all progestogens are the same molecule, and the choice between them can influence your risk profile.
How Progesterone Is Typically Taken
Oral micronized progesterone is the most commonly prescribed form for postmenopausal women. It’s usually taken at bedtime to take advantage of its sleep-promoting properties. The specific regimen depends on where you are in menopause.
- Continuous regimen: For women who are clearly postmenopausal (periods have stopped for at least 12 months), the standard approach is 100 mg of micronized progesterone taken every day alongside estrogen. This avoids monthly bleeding.
- Cyclic regimen: For women who are perimenopausal or recently postmenopausal, the typical approach is 200 mg of micronized progesterone for 12 to 14 days of each 28-day cycle, taken alongside continuous estrogen. This regimen produces a predictable monthly withdrawal bleed.
What It Doesn’t Appear to Do
Progesterone does not appear to significantly affect blood pressure, weight, waist circumference, total cholesterol, LDL cholesterol, or triglycerides. A three-month randomized trial in healthy early postmenopausal women found no meaningful differences in any of these measures between progesterone and placebo groups. The one notable exception was HDL cholesterol (“good” cholesterol), which dropped by about 7.7% on progesterone. This is a recognized trade-off, though the clinical significance of that modest decrease in the context of overall hormone therapy remains a topic of discussion.
Progesterone also did not affect blood vessel function or markers of inflammation and blood clotting in that trial, suggesting it’s relatively neutral on the cardiovascular system over the short term.
The Bigger Picture on Timing
Progesterone is one piece of a broader hormone therapy decision. Current guidance from the North American Menopause Society holds that for women under 60 or within 10 years of menopause onset, the benefit-risk ratio of hormone therapy is favorable for treating hot flashes, night sweats, and preventing bone loss. For women who start more than 10 years after menopause or who are over 60, the balance shifts because absolute risks of heart disease, stroke, and blood clots increase. The type, dose, route, and duration of therapy all influence the risk profile, which is why hormone therapy is meant to be individualized and periodically reassessed rather than treated as a one-size-fits-all prescription.